Targeting chemotherapy using lipiodol as a carrier of anticancer drugs for hepatocellular carcinoma and metastatic liver cancer.:Targeting chemotherapy using lipiodol as a carrier of anticancer drugs for hepatocellular carcinoma and metastatic liver cance

概要

論文の詳細を見る
I have found that the arterially injected lipid lymphographic agent, lipiodol ultrafluid, remaines selectively in hepatocellular carcinoma(HCC)and other malignant solid tumors. Using this characteristic nature of lipiodol, targeting cancer chemotherapy was achieved. It was shown that anticancer drug had to he dissolved in lipiodol and diffused out gradually from the agent in order to achieve targeting cancer chemotherapy. SMANCS/lipiodol, mitomycin C/lipiodol, aclarubicin/lipiodol and doxorubicin/lipiodol were successfully developed. Clinically, these oily anticancer agents were administered to 281 patients with HCC and 98 patients with metastatic liver cancer. Remarkable anticancer activities were proved based on decreased in tumor marker(AFP and CEA level decreased in 92%and 73%of the cases, respectively)and reduction in tumor size(in 94% of the patients with HCC and 47% of the cases with metastatec liver cancer). It was proved that survival period of the patients with unresectable tumors was definately prolonged (one year and two years survival rates of HCC and metastatic liver cancer were 64%, 26% and 58%, 21% respectively). Neither hernatosuppression nor any side effects due to anticancer drugs were observed.
日本DDS学会の論文